

INDUSTRY SYMPOSIUM DURING THE 32ND EUROPEAN CONGRESS ON OBESITY, TAKING PLACE
11-14 MAY 2025 IN MALAGA, SPAIN

Pathways to health with GLP-1 receptor agonism – from proteomic footprint to clinical outcomes

Monday 12 May 2025, 13.30–15.00 CEST

Conference Room 2, FYCMA Palacio de Ferias y Congresos de Málaga, Spain

Chaired by:

*Associate Professor
Ania Jastreboff,
MD, PhD*



Including expert faculty:

*Associate Professor
Christoffer Clemmensen,
PhD*



*Professor
Kirsi Pietiläinen,
MD, PhD, MSc*



*Professor Filip Knop,
MD, PhD,
Novo Nordisk*



5 minutes

Welcome

Ania Jastreboff

15 minutes

GLP-1: more than an incretin?

Part 1: Making use of the many facets of GLP-1 mode of action

Part 2: Clinical impact with a proteomic footprint

Christoffer Clemmensen

5 minutes

Audience polling

15 minutes

Health improvements with GLP-1 receptor agonism beyond weight

Kirsi Pietiläinen

5 minutes

Audience polling

15 minutes

New pathways to health: Have we unlocked the full potential of GLP-1RAs?

Filip Knop

5 minutes

Audience polling

20 minutes

Panel discussion: Addressing opportunities and future directions with GLP-1RA therapy

All faculty

5 minutes

Closing remarks

Ania Jastreboff



Lunch will be provided as part of the symposium